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Background. Development of rapid diagnostic tests for tuberculosis is a global priority. A  whole proteome screen identi-
fied Mycobacterium tuberculosis antigens associated with serological responses in tuberculosis patients. We used World Health 
Organization (WHO) target product profile (TPP) criteria for a detection test and triage test to evaluate these antigens.
Methods. Consecutive patients presenting to microscopy centers and district hospitals in Peru and to outpatient clinics at a 
tuberculosis reference center in Vietnam were recruited. We tested blood samples from 755 HIV–uninfected adults with presumptive 
pulmonary tuberculosis to measure IgG antibody responses to 57 M. tuberculosis antigens using a field-based multiplexed serological 
assay and a 132-antigen bead-based reference assay. We evaluated single antigen performance and models of all possible 3-antigen 
combinations and multiantigen combinations.
Results. Three-antigen and multiantigen models performed similarly and were superior to single antigens. With specificity 
set at 90% for a detection test, the best sensitivity of a 3-antigen model was 35% (95% confidence interval [CI], 31–40). With 
sensitivity set at 85% for a triage test, the specificity of the best 3-antigen model was 34% (95% CI, 29–40). The reference assay 
also did not meet study targets. Antigen performance differed significantly between the study sites for 7/22 of the best-performing 
antigens.
Conclusions. Although M. tuberculosis antigens were recognized by the IgG response during tuberculosis, no single antigen or 
multiantigen set performance approached WHO TPP criteria for clinical utility among HIV-uninfected adults with presumed tuber-
culosis in high-volume, urban settings in tuberculosis-endemic countries.
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 Despite advances in rapid molecular diagnostic techniques for 
tuberculosis, an unmet need remains for a point-of-care non-
sputum-based test [1]. The World Health Organization (WHO) 
has defined high-priority target product profiles (TPPs) for 
tuberculosis diagnostics [2]. These include a rapid nonspu-
tum-based test for detecting tuberculosis with the purpose of 
initiating tuberculosis treatment on the same day (tubercu-
losis detection test henceforth) and a community-based tri-
age or referral test for differentiating patients with signs and 
symptoms of active tuberculosis who need referral for further 
confirmatory testing from those who do not have tuberculosis 
(tuberculosis triage test henceforth). Serological tests such as 
lateral flow assays are appealing for these applications due to 
their simplicity, lack of specimen processing requirements, and 
implementation record. However, performance of serodiagnos-
tics for tuberculosis has been disappointing, leading the WHO 
to issue a strong recommendation against the use of serologi-
cal tests commercialized for the diagnosis of active tuberculo-
sis [3, 4]. In the WHO policy statement, further research was 
encouraged, specifically with representative populations with 
presumptive tuberculosis in studies with prospective follow-up 
and blinding [4].
One reason why serological diagnosis of tuberculosis has been 
challenging is that immunoglobulin G (IgG) responses to tuber-
culosis are heterogeneous across patient populations and most 
tuberculosis serologic tests use a single or small number of anti-
gens [5–9]. Therefore, FIND, a nonprofit organization that ena-
bles diagnostic development for poverty-related diseases, has 
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been systematically working to define the diagnostic potential 
of tuberculosis serological responses. Using a high-throughput 
expression system, the entire tuberculosis proteome was tested 
with globally collected sera from more than 500 patients with 
tuberculosis disease or nontuberculous pulmonary disease [6]. 
Although antibody responses were detected against approxi-
mately 10% (or 484 proteins) of the bacterial proteome, a much 
smaller fraction generated responses that might distinguish active 
tuberculosis from nontuberculous pulmonary disease. We pri-
oritized proteins that exhibited the best discriminating capacity 
toward the development of new tuberculosis detection or tuber-
culosis triage tests.
Here, we report the diagnostic performance of a custom, 
portable multiplexed serology assay (MBio Diagnostics) that 
was used to measure antibody responses to 57 selected antigens 
in blood from more than 750 prospectively enrolled adults with 
presumptive pulmonary tuberculosis at 2 trial sites in Vietnam 
and Peru. Antibody response to a broader set of 132 antigens 
in frozen sera was also measured using a multiplex bead-based 
Luminex assay at a reference research laboratory.
METHODS
Study Design
Adults who presented to ambulatory healthcare centers with symp-
toms suggestive of pulmonary tuberculosis in Peru and Vietnam 
were consecutively enrolled in the study. The site in Peru is a 
research institute in Lima that recruits patients from microscopy 
centers and district hospitals in a high tuberculosis prevalence 
area. The site in Vietnam is a tuberculosis and lung disease ref-
erence center in Ho Chi Minh City that recruits patients from its 
outpatient clinic. Inclusion and exclusion criteria for entry into the 
trial are detailed in Supplementary Table 1, and criteria to exclude 
recruited patients from the analysis are provided in Supplementary 
Appendix 1. Patient characteristics, comorbidities, and tuber-
culosis history were recorded. Human immunodeficiency virus 
(HIV)–positive individuals were excluded from this feasibility 
study in view of potentially altered serological responses [10]. 
Written informed consent was obtained from all patients. Study 
participation did not alter the standard of care. Figure 1 depicts 
the patient and specimen flow. Recruitment was done in 2 phases: 
phase 1 was used to validate the field-based MBio platform against 
the reference assay before proceeding to the larger phase 2.
Sample Procedures
At least 2 sputum samples were collected from each patient 
and tested with direct smear microscopy, solid and liquid cul-
ture, and with Xpert® MTB/RIF (Cepheid, Sunnyvale), when 
available. The presence of Mycobacterium tuberculosis com-
plex in cultures was confirmed by MPT 64 antigen detection 
(Capilia TB, Tauns Laboratories, Japan). Serum (SE), whole 
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Figure 1. Patient and specimen flow. Abbreviations: HIV, human immunodeficiency virus; LJ, Löwenstein–Jensen solid medium; MGIT, BACTEC mycobacteria growth 
indicator tube 960 culture; NALC-NaOH Decon., N-acetyl-L-cysteine-sodium hydroxide decontamination; NMI, Natural and Medical Sciences Institute at the University of 
Tübingen; Xpert, Xpert® MTB/RIF.
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blood (WB), and frozen serum (FZ) were collected for analysis 
(Supplementary Appendix 2).
Case Definitions
Supplementary Table 2 summarizes the case definitions. Patients 
were categorized based on clinical and microbiological results. 
Patients with positive M. tuberculosis cultures were diagnosed 
as definite tuberculosis and subcategorized into smear-positive 
and smear-negative groups. Participants who were smear nega-
tive and culture negative but responded to empiric tuberculosis 
treatment were classified as “clinical tuberculosis.” Participants 
who were smear negative and culture negative on all sputum 
samples and who exhibited symptom resolution in the absence 
of tuberculosis treatment at the 2-month follow-up visit were 
classified as “non-tuberculosis disease.”
Antigen Selection
The antigen selection process is described in Supplementary 
Appendix 3 and Supplementary Figure 1. In summary, 62 anti-
gens from the whole proteome screen [6] were selected for 
expression and purification on the basis of odds ratios, area under 
the curve (AUC), or high model importance in random forest 
analysis. An additional 41 antigens were selected in independent 
research studies performed by institutions that collaborate with 
FIND. The resulting antigen panel was prescreened with 1321 
patient sera by a multiplex Luminex assay [11] to define the sub-
set of 57 recombinant antigens (Figure 2B) used in this study. 
To validate the down-selection of target antigens, we retained 
the Luminex assay and added additional antigens such that 
this platform contained 132 antigens (including recombinant 
proteins, fusion proteins, antigen cocktails, and native protein 
preparations; Figure 2C). There were 93 unique antigens. The 
antigen list and expression, purification, and quality details are 
listed in Supplementary Appendix 4 and Supplementary Table 3.
MBio Multiplexed Serological Assay
The MBio multiplexed immunoassay system uses disposable 
cartridges that have a 2-dimensional array of antigens and 
controls along with a laptop-connectable reader (SnapEsi; 
Supplementary Appendix 5)  [12]. Briefly, diluted sample is 
added to the cartridge and, after an incubation and wash, flu-
orescently labeled anti-human IgG is used to measure anti-
gen-bound human IgG for each spot in the array.
Serological Luminex Assay
The multiplex bead-based Luminex assay, which measures IgG 
antibodies in FZ, was performed as described in Planatscher 
et al [13] and Supplementary Appendix 6.
Diagnostic Performance of Single Antigens and Antigen Models
The WHO TPP for the tuberculosis detection test and tubercu-
losis triage test are summarized in Table 1, alongside the study 
targets for the MBio and Luminex platforms. The performance 
of antigens (or antigen sets) were evaluated against the follow-
ing 3 targets: tuberculosis detection test sensitivity at preset 
specificity, tuberculosis triage test specificity at preset sensitiv-
ity, and AUC (Supplementary Appendix 8).
Statistical Analysis for Multiantigen Combinations
Generalized linear models (GLMs), generalized additive mod-
els (GAMs), and naive Bayes (NB) with 8-fold cross-validation 
were used to test all possible 3-antigen combinations and to 
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Figure 2. Summary of patient and antigen selection. A, Recruitment flow diagram for patients enrolled in the study. B, MBio field platform antigens. C, Luminex reference 
platform antigens. All MBio field platform antigens were also measured on the Luminex reference platform. Some of the antigens used have the same Rv number (see http://
tuberculist.epfl.ch/) and amino acid sequence, but were provided by different suppliers or expressed in different production strains. Therefore, the number of unique antigens 
is shown in brackets. A comprehensive list can be found in Supplementary Table 3. Abbreviations: CRF, Case report form; HIV, human immunodeficiency virus.
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identify a subset of antigen combinations by stepwise regression 
for each platform and sample type (Supplementary Appendixes 
9 and 10). The models were set to optimize sensitivity at preset 
specificity for tuberculosis detection tests, specificity at preset 
sensitivity for the tuberculosis triage tests, and AUC.
RESULTS
Study Participants
A total of 844 eligible patients with presumptive tuberculosis were 
recruited to the study (Figure 2A). A  total of 73 were excluded 
from analysis due to new diagnosis of HIV or discrepancies in 
study documentation, microbiological test results, or study sample 
collection (Figure 2A, Supplementary Appendix 1). There were 16 
additional exclusions due to missing MBio data or cartridge errors 
(Figure 2A). A total of 755 adults were therefore eligible for anal-
ysis with 447 definite tuberculosis cases, 13 cases of clinical tuber-
culosis, and 295 of non-tuberculosis disease (Figure 2A, Table 2).
Validation of MBio and Luminex Platforms
In phase 1, samples from 184 patients (Supplementary Table 4) 
were used to validate the MBio system, which showed high con-
cordance with the Luminex assay (Supplementary Appendix 
7) and met all endpoints at both sites [14]. The Luminex assay 
had intra- and inter-assay coefficients of variation of <20% for 
128/132 antigens (Supplementary Appendix 6). Antigen cou-
pling efficiency of all His-tagged antigens (n = 125) was con-
firmed using an anti-His antibody (Supplementary Table  11). 
MBio analysis was based on all 755 patients; for Luminex, we 
focused on the larger phase 2 (571 valid results), as the signal 
ranges in the 2 experimental runs did not permit combination.
Single Antigen Performance
When we analyzed performance of the 57 single antigens on 
the MBio platform, we identified 22 top-ranking antigens 
(Supplementary Table  5). The best antigen for a tuberculo-
sis detection test with a predefined specificity of 90% was 
Rv2031c_1a, with highest sensitivity of 25% (95% confi-
dence interval [CI], 21–29) on fresh serum. The best antigen 
for a tuberculosis triage test with a predefined sensitivity of 
85% was Rv1860_1a, with highest specificity of 32% (95% 
CI, 26–37) on frozen serum (Supplementary Figure  2). 
Comparing the performance of the same 57 antigens on the 
Luminex platform, we found that although AUCs tended to 
be higher on Luminex, only 5 of the 22 top-ranked antigens 
performed significantly better than on MBio (Figure  3A, 
Supplementary Table  5). The highest AUC was 0.69 
Table  1. World Health Organization–Endorsed Performance Targets and Prespecified Study Targets for Judging Performance of Antigen Panels for 
Diagnosis of Tuberculosis 
WHO Target Product 
Profile Name
WHO Target Product Profile 
Requirements
Study Target
Luminex Reference 
Platform
Study Target
MBio Field Platform Target
Rapid, biomarker-based 
nonsputum-based test for 
detecting tuberculosis
Tuberculosis detection 
test
Specificity ≥98%
Sensitivity ≥65%
Specificity set at 95%
Sensitivity target: ≥60%
Frozen serum
Specificity set at 90%
Sensitivity target: ≥55%
Indeterminate rate >10%
Fresh diluted serum or diluted 
whole blood”
Target population: “adults 
and children includ-
ing those who are 
HIV-positive and with 
presumptive active pul-
monary TB or extra-pulmo-
nary TB in countries with 
a medium prevalence to a 
high prevalence of TB as 
defined by WHO.”
Study population: Prospective consecutively presenting HIV-uninfected 
adults with presumptive pulmonary tuberculosis attending:
• Microscopy centers or district hospitals in Lima, Peru (WHO high-preva-
lence country)
• Outpatient clinic at tuberculosis and lung disease hospital, Ho Chi Minh 
City, Vietnam (WHO high-prevalence country)
Community-based 
triage or referral test 
to identify people 
with presumptive 
tuberculosis
Tuberculosis triage 
test
Sensitivity ≥90%
Specificity ≥70%
Sensitivity set at 90%
Specificity target: ≥60%
Frozen serum
Sensitivity set at 85%
Specificity target: ≥55%
Indeterminate rate >10%
Fresh diluted serum or diluted 
whole blood
Target population: “adults 
and children with signs 
and symptoms of active 
pulmonary TB in countries 
with a medium prevalence 
to a high prevalence of TB 
as defined by WHO.”
Study population: Prospective consecutively presenting HIV-uninfected 
adults with presumptive pulmonary tuberculosis attending:
• Microscopy centers or district hospitals in Lima, Peru (WHO high-preva-
lence country)
• Outpatient clinic at tuberculosis and lung disease hospital, Ho Chi Minh 
City, Vietnam (WHO high-prevalence country)
Abbreviations: HIV, human immunodeficiency virus; WHO, World Health Organization. Target Product Profiles can be accessed on-line under http://www.who.int/tb/publications/tpp_report/
en/ [2]
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(Rv2031c_1a) on Luminex and 0.64 (RV1860_1a, MBio FZ) 
on MBio (Supplementary Table 5).
When we analyzed the performance of the 75 additional 
antigens that were only measured on the Luminex plat-
form, we identified antigens that performed slightly better 
(Supplementary Table 6), with the sensitivity of the best anti-
gen for the tuberculosis detection test being 31% (95% CI, 
27–36) for Rv1886_5. The highest AUC of a single antigen on 
Luminex was 0.72 from WCL_H37Rv_6.
Influence of Study Site and Previous History of Tuberculosis on 
Performance
Given the study design and the study participants’ characteris-
tics (Table 2), we carried out post hoc subanalyses to determine 
whether performance varied between the study sites and by the 
participants who had a previous history of tuberculosis.
Figure 3B shows immunological responses of 755 patients to 
the 22 highest ranked antigens on the MBio assay categorized by 
study site. Patient-to-patient antibody response was variable, and 
Figure 3. Summary of individual antigen performance. A, Area under the curve (AUC) histograms by sample type and platform for the 57 antigens that were measured on 
both platforms. AUCs of fresh (serum, whole blood) and frozen (serum) samples from MBio are in the same range, and no difference per sample type could be observed. There 
was a tendency for higher AUCs from Luminex compared to MBio, but differences were only significant for 5 antigens (Supplementary Table 5). Approximate AUC targets (blue 
and green lines) were estimated based on study targets (AUC estimated by receiver operating characteristic (ROC) curve fitting through the study target points using a binor-
mal model) and were not met by single antigens. B, Heterogeneous antibody response pattern of 755 tuberculosis patients. The heat map shows the reactivity of sera (stand-
ardized z-scores of MBio fresh serum intensity signals) to the 22 highest ranked MBio antigens. Abbreviations: FZ, frozen serum; SE, fresh serum; WB, fresh whole blood. 
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false-positive reactivity can be observed in the non-tuberculosis 
disease groups of both sites. Antibody responses to some antigens, 
including the top 3 MBio antigens, were dependent on study site. 
Antibody response against Rv1860_1a was higher in the Vietnam 
cohort, resulting in a significantly higher tuberculosis detec-
tion test sensitivity (38% in Vietnam vs 10% in Peru). Antibody 
response against Rv2031c_1a and Rv1886_2 had significantly 
higher AUCs in Peru due to increased reactivity in the Peruvian 
definite tuberculosis group (Figure 3B, Supplementary Table 9).
Given the relatively high proportion of patients with a his-
tory of previous tuberculosis in our cohort (Table 2), we also 
carried out a subanalysis where patients with a history of tuber-
culosis or unknown history of tuberculosis were excluded 
(Supplementary Table 10). There were no significant differences 
in AUC when compared to analysis of the whole cohort.
Three-Antigen Models
We then determined whether combinations of responses to 
3 antigens would improve diagnostic performance. We used 
GAM, GLM, and NB models for all possible 3-antigen sets for 
the 57 antigens measured on MBio (29 260 input sets). The best 
tuberculosis detection sensitivity was 35% (95% CI, 31–40) for 
the combination of Rv1860_1a, Rv1886_2, and Rv3881c_1a 
(Table 3A). The best tuberculosis triage test specificity was 34% 
(95% CI, 29–40) for the combination of Rv1860_1a, Rv1886_2, 
and Rv3874_1a (Table 3B), which is significantly above the per-
formance of the best single antigens. The frequency of the top 
22 ranked single antigens in the best 3-antigen models is pre-
sented in Supplementary Table 7, confirming that antigens with 
a high single-antigen performance occur very frequently in the 
best models.
Table 2. Characteristics of Study Participants
Characteristic
Peru Vietnam Total
Non- 
Tuberculosis 
Disease 
(n = 167)
Definite 
Tuberculosis 
(n = 230)
Clinical 
Tuberculosis 
(n = 8)
Non-Tuberculosis 
Disease (n = 128)
Definite 
Tuberculosis 
(n = 217)
Clinical 
Tuberculosis 
(n = 5)
Non- 
Tuberculosis 
Disease (n = 295)
Definite 
Tuberculosis 
(n = 447)
Clinical 
Tuberculosis 
(n=13)
Age, y
41.5 ± 15.7 
(P < .0001)a
31.6 ± 14.0 29.0 ± 13.1 45.0 ± 16.3 
(P < .0001)a
37.6 ± 13.5 56 ± 10.2 43.0 ± 16.0 
(P < .0001)a
34.5 ± 14.1 29.3 ± 18.0
Gender
Male 75 (44.9%) 
(P = 0.001)b
144 (62.6%) 4 (50.0%) 95 (74.2%) 
(P = 0.40)b
146 (67.2%) 4 (80.0%) 170 (57.6%) 
(P = 0.13)b 
290 (64.9%) 8 (61.5%)
Female 92 (55.1%) 86 (37.4%) 4 (50.0%) 33 (25.8%) 71 (32.7%) 1 (20.0%) 125 (43.4%) 157 (35.1%) 5 (38.5%)
Enrollment body mass index
Underweight 
(<18.5)
2 (1.2%) 
(P < .0001)c
21 (9.1%) 2 (25.0%) 46 (36.0%) 
(P = .0006)c
96 (44.2%) 2 (40.0%) 48 (16.3%) 
(P < .0001)c
117 (26.2%) 4 (30.8%)
Normal (≥18.5 + 
<25)
97 (58.1%) 163 (70.9%) 6 (75.0%) 75 (58.6%) 118 (54.4%) 3 (60.0%) 172 (58.3%) 281 (62.9%) 9 (69.2%)
Overweight 
(≥25 + <30)
50 (29.9%) 39 (17.0%) 0 (0%) 7 (5.5%) 3 (1.4%) 0 (0%) 57 (19.3%) 42 (9.4%) 0 (0%)
Obese (≥30) 16 (9.6%) 7 (3.0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 16 (5.4%) 7 (1.6%) 0 (0%)
Tuberculosis history
 No 124 (74.3%) 
(P = .0004)b 
203 (88.3%) 7 (87.5%) 24 (18.8%) 
(P < .0001)b 
88 (40.6%) 5 (100%) 148 (50.2%) 
(P < .0001)b 
291 (65.1%) 12 (92.3%)
 Yes 40 (24.0%) 26 (11.3%) 0 (0%) 13 (10.2%) 8 (3.7%) 0 (0%) 53 (18.0%) 34 (7.6%) 0 (0%)
 Not done 3 (1.8%) 1 (0.4%) 1 (12.5%) 91 (71.1%) 121 (55.8%) 0 (0%) 94 (31.9%) 122 (27.3%) 1 (7.7%)
Smear statusd,e
Smear negative 167 (100.0%) 50 (21.7%) 8 (100%) 128 (100%) 108 (49.8%) 5 (100%) 295 (100%) 158 (35.4%) 13 (100%)
 Smear positive 0 (0%) 180 (78.3%) 0 (0%) 0 (0%) 109 (50.2%) 0 (0%) 0 (0%) 289 (64.7%) 0 (0%)
Xpert® MTB/RIFe
Negative 120 (72%) 10 (4%) 5 (63%) 122 (95%) 46 (21%) 4 (80%) 242 (82%) 56 (12%) 9 (69%)
Positive 0 (0%) 167 (73%) 0 (0%) 0 (0%) 171 (79%) 0 (0%) 0 (0%) 338 (76%) 0
No result (inde-
terminate or 
no result)
47 (28%) 53 (23%) 3 (37%) 6 (5%) 0 (0%) 1 (20%) 53 (18%) 53 (12%) 4 (31%)
Data from phases 1 and 2, excluding patients whose final diagnosis was indeterminate.
aLogistic regression.
bFisher exact test.
cMantel-Hanzel χ2 test.
dNo P value since it is used to calculate outcome, final diagnosis.
eSmear-positive/culture-neegative and Xpert® MTB/RIF -positive/culture-negative individuals were excluded from the analysis where smear or Xpert® MTB/RIF results were available.
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Multiantigen Models
We also looked at models that contained larger numbers of 
antigens, with stepwise regression yielding 4 to 12 antigens 
depending on model and sample type. The best model for 
tuberculosis detection involved 7 antigens and had a sensitiv-
ity of 36% (95% CI, 32–41). The best model for tuberculosis 
triage test had specificity of 37% (95% CI, 31–43) based on 9 
antigens. We further conducted the same subanalyses using 
only the 439 patients with no tuberculosis history. Similar 
to the subanalysis for single antigens, performance did not 
significantly improve (tuberculosis detection test sensi-
tivity of 37% and tuberculosis triage test specificity of 40% 
respectively).
Evaluation of Diagnostic Performance Against WHO Target Product 
Profiles
Finally, we compared the performance of single antigens, 
3-antigen models, and multiantigen models on both plat-
forms against each other, against the serological tests evaluated 
by the WHO in 2008, and against the study and TPP targets 
(Figure 4). The 3-antigen models performed significantly bet-
ter than single antigens and previously evaluated tests by the 
WHO, but multiantigen combinations did not further improve 
performance. No model on either platform approached the 
study or TPP targets.
DISCUSSION
We carried out a prospective diagnostic study with more than 
750 HIV-uninfected adult patients with presumed tubercu-
losis in high-volume, urban settings in 2 high-burden coun-
tries and with 2 multiplexed antibody detection platforms: a 
field-based platform (MBio) and a reference laboratory plat-
form (Luminex). Given the heterogeneous nature of antibody 
responses in tuberculosis, we used a large pool of antigens 
selected from the immunoproteome screen [6] and evaluated 
their individual performance, as well as the predictive abilities 
of combinations. Although 3-antigen and multiantigen models 
performed better than single antigens, our robust and system-
atic approach showed that no combination met performance 
targets for tuberculosis detection tests or tuberculosis triage 
tests on either platform.
The antigens that performed best in our study have also per-
formed well in other studies reported in the literature. In keep-
ing with the fact that antigens were selected from the whole 
proteome screen [6], 20 of the 22 top antigens from this study 
were highly ranked in the whole proteome screen, in Khan et al 
[9], or in both (Supplementary Table 8). The secreted glycopro-
tein Rv1860 (MPT32, Apa) is present in immunodominant frac-
tions of M. tuberculosis H37Rv culture filtrate [15] and reached 
the highest odds ratio in the M. tuberculosis proteome screen 
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TPP, target product profile; WHO, World Health Organization.
Table 3A. Number of Patients Grouped by Patient Classification for the 
Best 3-Antigen Model (Rv1860_1a, Rv1886_2, Rv3881c_1a, GLM, fresh 
serum, MBio) for a Tuberculosis Detection Test with Preset Specificity at 
90%.
Definite
Tuberculosis
(n = 447)
Clinical
Tuberculosis
(n = 13)
Non-
Tuberculosis
Disease
(n = 295)
Total
(n = 755)
Predicted positive by the 
best 3-antigen
model
156 0 29 185
Predicted negative by the
best 3-antigen
model
291 13 266 570
Table  3B. Number of Patients Grouped by Patient Classification for 
the Best 3-Antigen Model (Rv1860_1a, Rv1886_2, Rv3874_1a, GAM, fresh 
serum, MBio) for a Tuberculosis Triage Test with Preset Sensitivity at 85%.
Definite
Tuberculosis
(n = 447)
Clinical
Tuberculosis
(n = 13)
Non-
Tuberculosis
Disease
(n = 295)
Total
(n = 755)
Predicted positive by the 
best 3-antigen
model
380 9 194 583
Predicted negative by the
best 3-antigen
model
67 4 101 172
Abbreviations: GAM, general additive model; GLM, generalized linear model.
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[6], as well as in other studies [7, 9]. The 16-kDa cell-wall pro-
tein Rv2031c (HspX) was also identified in the proteome screen 
[6, 16]. Rv1886c, a protein of the antigen 85 (Ag85) complex, is 
involved in cell wall mycolylation and is immunodominant [9, 
16]. A native preparation of the Ag85 complex and an additional 
production batch of Rv1886c were used in the Luminex assay 
and also performed well. Only 2 antigens from the Top 22 were 
not previously identified: a succinate dehydrogenase (Rv3319) 
and fructose 1,6-bisphosphatase (Rv1099), which is involved 
in gluconeogenesis [17] and was elevated in infected Rhesus 
macaques in a tuberculosis outbreak [18]. Superior performance 
of serological tests has been reported in other studies, although 
the comparison groups were often asymptomatic patients rather 
than patients with presumptive tuberculosis subsequently clas-
sified as non-tuberculosis disease [19–22]. Differences between 
our results and those of previous studies could also be attrib-
utable to patient population, design, and sample size. While 
previous studies have often used single-center recruitment, ret-
rospective designs, and smaller sample sizes, our study included 
prospective consecutive recruitment of patients with presump-
tive tuberculosis in two high tuberculosis prevalence countries. 
In the assessment of study quality using the QUADAS-2 frame-
work, our study has a relatively low risk of bias (Supplementary 
Table 12). In contrast, the metaanalysis of Steingart et al [23] 
identified “very serious limitations” and “significant risk of bias” 
for most of the studies, which might explain overestimation of 
test performance. Using the same search terms as Steingart et al, 
restricted to adults and pulmonary tuberculosis, we identified 
2 publications through PubMed since their metaanalysis that 
evaluated patients with presumptive tuberculosis [7, 24]. One 
was a diagnostic study with reported sensitivity of 35.6% and 
specificity of 93.7% [24], which is similar to our results.
Our study has several limitations. Performance differences 
between the 2 platforms (Figure 3A) may be due to a degree 
of variability introduced by day-to-day field testing vs frozen 
sample batch testing in a research laboratory. However, plat-
form AUC differences were only significant for 5 antigens 
(Supplementary Table 5), and MBio showed reasonable AUC 
agreement across sample types (Figure 3A). We recognize that 
expression systems and antigen purity matter and, therefore, 
included native antigen preparations and, where available, sev-
eral versions of the same antigen from multiple suppliers on 
the Luminex platform. Notably, five of the highest-perform-
ing antigens on Luminex were native protein preparations 
that were added after the MBio platform assay was finalized. 
However, these showed only marginal improved performance 
over other antigens (eg, best performing native protein prepa-
ration on Luminex, WCL H37Rv_6, AUC = 0.72 vs best per-
forming single antigen on Luminex, Rv2031c_1a, AUC = 0.69). 
The high performance of native proteins from M. tuberculosis 
strains compared to proteins expressed in Escherichia coli may 
be explained by different post-translational modifications. 
Expression of selected antigens in Mycobacterium smegmatis 
might therefore be advantageous [25, 26]. The mode of anti-
gen display may also influence antibody binding. However, we 
could only see marginal differences in diagnostic performance 
when we used two independent immobilization technologies 
(antigen printing on plastic substrates and covalent antigen 
coupling to beads).
As noted in previous IgG biomarker studies, there is 
remarkable patient-to-patient variability in antibody 
responses [5–7, 9]. We found the same heterogeneity in indi-
vidual responses and also that performance of 7 of the 22 
high ranked antigens were significantly associated with study 
location (Figure  3B). Differences in the referral pathways, 
genetic diversity among tuberculosis strains, host genetic 
differences [27], differing vaccination status, or exposure to 
environmental mycobacteria might explain some of this var-
iability [7]. Patients being at different stages of the spectrum 
of latent to active tuberculosis disease could also contribute 
[28–30]. Latent tuberculosis infection was not determined 
by tuberculin skin test or interferon gamma release assay 
in our study, which is a limitation. Categorized radiological 
interpretations of the chest radiographs were not available; 
therefore, we could not analyze data based on cavitary sta-
tus. Subanalyses excluding patients with a prior history with 
tuberculosis showed comparable results to the whole data-
set. Our findings cannot be applied to children, people living 
with HIV with presumptive tuberculosis, or to systematic 
screening or active case-finding.
Our results confirm that a defined pool of antigens are recog-
nized by the IgG antibody response during active tuberculosis 
and that no single antigen or combination is sufficient to clearly 
identify patients with active tuberculosis disease [6, 7, 9, 16, 31, 
32]. The results of our study of HIV-uninfected patients with pre-
sumptive tuberculosis from high-volume settings in tuberculosis 
endemic countries, which evaluated multiple antigens, sample 
types, and 2 test platforms, suggests that a conventional anti-
gen-based IgG detection test is unlikely to meet requirements 
for novel tuberculosis diagnostics in symptomatic patients. This 
is in concordance with systematic reviews and metaanalyses of 
serologic testing in tuberculosis [3, 4], although combination 
with other biomarkers and IgG properties such as FcR-binding 
and glycosylation characteristics may have potential [33, 34].
Supplementary Data
Supplementary materials are available at Clinical Infectious Diseases online. 
Consisting of data provided by the author to benefit the reader, the posted 
materials are not copyedited and are the sole responsibility of the author, so 
questions or comments should be addressed to the author.
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